Skyrizi 180 MG/1.2 ML on-body 1.2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F0ZM1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,467
Award facts
- Contract value 100% obligated
- $12,467.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,467 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 180 mg/1.2 ml on-body injections on January 8, 2026, with completion scheduled for January 30, 2026. This firm fixed-price, non-set-aside contract is performed at the contractor's Conshohocken, Pennsylvania facility and represents a task order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. The parent company, Cencora, Inc. (which operates as AmerisourceBergen), holds a significant $999,999,999 IDC through December 2031 that serves as the primary vehicle for supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems. The company demonstrates substantial capability in fulfilling diverse pharmaceutical supply requirements through its established DLA contract vehicle, which covers specialty medications, brand-name and generic drugs, vaccines, and specialized medical supplies across multiple therapeutic domains. This delivery order for SKYRIZI, a dermatology biologic used to treat plaque psoriasis and other inflammatory conditions, exemplifies the contractor's role in providing specialized pharmaceutical products essential to military treatment facilities and Defense Health Agency operations.
Quick answers
Who was awarded contract SPE2DR26F0ZM1?
SPE2DR26F0ZM1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F0ZM1 worth?
The government has obligated $12,467 on SPE2DR26F0ZM1.
Is contract SPE2DR26F0ZM1 an order under another contract?
Yes. SPE2DR26F0ZM1 is a delivery order under SPE2DR25D1205, an indefinite delivery contract.
Was contract SPE2DR26F0ZM1 competed?
The extent of competition for SPE2DR26F0ZM1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award